Physician profile
Caleb A Smith
NPI 1568903110
$6,464.64
in general payments reported to CMS, 2019-2025
37 companies · $1,574 in 2025
The $1,574 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $234 · 2021: $534 · 2022: $1,007 · 2023: $1,582 · 2024: $1,535 · 2025: $1,574.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,690.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,690.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $815.95 | 2020-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals Lp | $658.64 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $541.14 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $447.58 | 2022-2025 | |
| Lilly USA, LLC | $427.25 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $365.90 | 2021-2025 | Prolia, Evenity, Otezla |
| Novo Nordisk INC | $356.24 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $337.73 | 2020-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $303.31 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $288.26 | 2022-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $247.58 | 2020-2025 | Jardiance, Synjardy, Ofev |
| Esperion Therapeutics, INC. | $234.96 | 2020-2025 | Nexletol |
| Lundbeck LLC | $168.42 | 2022-2025 | Vyepti |
| Takeda Pharmaceuticals U.S.A., INC. | $141.33 | 2020-2024 | Trintellix |
| Exact Sciences Corporation | $137.66 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caleb Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.